{"created":"2023-05-15T14:35:38.533197+00:00","id":45838,"links":{},"metadata":{"_buckets":{"deposit":"535404da-96d7-413e-a4dc-10ca349416ba"},"_deposit":{"created_by":1,"id":"45838","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"45838"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00045838","sets":["1"]},"author_link":["455846","455838","455847","455844","455841","455839","455840","455843","455842","455845"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2008-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"194","bibliographicPageStart":"192","bibliographicVolumeNumber":"19","bibliographic_titles":[{"bibliographic_title":"Annals of Oncology"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Ovarian cancer results in more deaths than any other gynecologic malignancy. In the\nUnited States and Japan, there are over 15,000 and 4,000 deaths from ovarian cancer per\nyear, respectively [1]. This high mortality rate can be attributed to the approximately\n75% of patients who are diagnosed with stage III and IV disease with intraperitoneal\ncarcinomatosis [2]. Although the five-year survival rate of patients in whom lymph\nnodes are the only site of metastasis, the so-called \"retroperitoneal stage IIIc\", ranges\nfrom 84 to 96%, higher than the 20-30% of intraperitoneal stage IIIc patients [3], we\nhave sometimes encountered cases of ovarian cancer with local recurrence in the lymph\nnodes which was completely unresectable at surgery and chemoresistant, resulting in\nsalvage chemotherapy. Therefore, a more potent treatment should be introduced for this\nsituation to achieve either disease-free survival or local control.\nHigh linear energy transfer (LET) particle therapy has various advantages in terms of\nradiobiological effects as well as dose distribution and has been expected to offer a\ntherapeutic advantage over conventional photon therapy. The biological advantages of\nhigh LET radiation, including carbon beam therapy, are summarized as a decreased\noxygen enhancement ratio, diminished capacity for sublethal and potentially lethal\ndamage repair, and diminished cell cycle-dependent radiosensitivity [4]. Thus, these\nadvantages prompted us to use carbon beam therapy for bulky recurrent ovarian tumor,\nwhich is considered to have a large fraction of hypoxic tumor.\nThe patient was a 68-year-old woman with ovarian cancer who was optimally treated\nby hysterectomy, bilateral salpingo-oophorectomy, omentectomy and pelvic and\npara-aortic lymphadenectomy in Feb.2003, followed by three courses of paclitaxel and\ncarboplatin (TJ) for right ovarian cancer, endometrioid type, grade 2, pT1cN0M0. Since\nlocal recurrence of ovarian cancer at the site of the right internal-iliac artery lymph node was detected in Nov.2004, six more courses of TJ were performed. The recurrent tumor\nhad grown to a maximum 8 cm in diameter despite several protocols of chemotherapy,\nincluding platinium, taxane, CPT-11 and gemcitabine. After we had confirmed no\nmetastasis besides the recurrence site with positron emission tomography using\nfluorine-18 fluorodeoxyglucose /CT (FDG-PET/CT), we decided to treat the lesion with\ncarbon beam therapy. Before the therapy, the patient gave written informed consent,\nand the study was approved by the local ethics committee and institutional review board\nof our hospital. Moreover, the patient underwent an operation in which a Goretex sheet\nwas inserted, the lesion was partially excised and an artificial anus was constructed to\nprotect the intestine and rectum adjacent to the tumor from injury by high LET particles.\nThe heavy-ion medical accelerator in Chiba is the first heavy ion accelerator specially\ndedicated to medicine in the world, and its design variables are based on the\nradiological requirements [5]. The carbon beam energy used was 350 to 400 MeV. As\nshown in Figs. A and B, anteroposterior, posteroanterior and lateral opposing ports were\nused for 16 fractions over 4 weeks with 4 fractions weekly, consequently, the total dose\nwas a 57.6 Gy equivalent dose. Through out the treatment, no severe side effects were\nobserved. At ten months after treatment, the pelvic tumor had drastically shrunk (Fig.C),\nand the patient has continued clinical disease free for 2 years.\nThis is the first report, to our knowledge, showing that carbon beam therapy was effective for recurrent ovarian cancer. The result is sufficiently encouraging to continue\nthe therapy in patients with metastatic, anti-cancer-drug-resistant ovarian cancer, as well\nas other types of gynecologic cancer.","subitem_description_type":"Abstract"}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0923-7534","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Niwa, Akihiro"}],"nameIdentifiers":[{"nameIdentifier":"455838","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Suzuki, Kyosuke"}],"nameIdentifiers":[{"nameIdentifier":"455839","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kato, Shingo"}],"nameIdentifiers":[{"nameIdentifier":"455840","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kajiyama, Hiraki"}],"nameIdentifiers":[{"nameIdentifier":"455841","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shibata, Kiyosumi"}],"nameIdentifiers":[{"nameIdentifier":"455842","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ino, Kazuhiko"}],"nameIdentifiers":[{"nameIdentifier":"455843","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakamura, Hisao"}],"nameIdentifiers":[{"nameIdentifier":"455844","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kikkawa, Fumitaka"}],"nameIdentifiers":[{"nameIdentifier":"455845","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"et.al"}],"nameIdentifiers":[{"nameIdentifier":"455846","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"加藤 眞吾","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"455847","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Carbon beam therapy in recurrent ovarian cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Carbon beam therapy in recurrent ovarian cancer"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2010-06-29"},"publish_date":"2010-06-29","publish_status":"0","recid":"45838","relation_version_is_last":true,"title":["Carbon beam therapy in recurrent ovarian cancer"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:59:00.180151+00:00"}